Uploaded August 2026 | Updated September 2026, 2 weeks ago
Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform
Following a decade of exploration from the 2014 NVIDIA GTC to the PreciousGPT model series, Insilico Medicine presents the industry's first multi-agent Virtual Aging Cell(VAC) platform with biological age as a core condition.
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), today announced the launch of its Virtual Aging Cell (VAC) Webpage alongside the preview of the company’s Multi-Agent driven VAC platform.
Virtual cells are digital models that leverage artificial intelligence (AI) and mathematical modeling to computationally simulate cellular biology and its underlying dynamic laws. They offer powerful capabilities to predict drug responses, elucidate disease mechanisms, and support target discovery.Recognized as a frontier technology, virtual cells were named one of the seven technology breakthroughs to watch in 2025 by Nature, quickly becoming a focal point of competitive research for top global teams.
However, most existing models rely predominantly on data collected at isolated time points, capturing cells as static snapshots. Their capacity to simulate dynamic temporal processes—such as cellular differentiation, reprogramming, and aging—as well as multi-scale interactions across biological hierarchies, remains markedly constrained. Living cells are not frozen biological units; rather, they are constantly undergoing dynamic processes including division, differentiation, aging, and environmental response. A cell's state is intricately shaped by intracellular molecular networks, intercellular communications, tissue microenvironments, and individual background parameters. Consequently, integrating the temporal axis, biological age, and external interventions into a unified computational framework has emerged as a crucial trajectory for the evolution of virtual cell research.
Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform
Following a decade of exploration from the 2014 NVIDIA GTC to the PreciousGPT model series, Insilico Medicine presents the industry's first multi-agent Virtual Aging Cell(VAC) platform with biological age as a core condition.
Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), today announced the launch of its Virtual Aging Cell (VAC) Webpage alongside the preview of the company’s Multi-Agent driven VAC platform.
Virtual cells are digital models that leverage artificial intelligence (AI) and mathematical modeling to computationally simulate cellular biology and its underlying dynamic laws. They offer powerful capabilities to predict drug responses, elucidate disease mechanisms, and support target discovery.Recognized as a frontier technology, virtual cells were named one of the seven technology breakthroughs to watch in 2025 by Nature, quickly becoming a focal point of competitive research for top global teams.
However, most existing models rely predominantly on data collected at isolated time points, capturing cells as static snapshots. Their capacity to simulate dynamic temporal processes—such as cellular differentiation, reprogramming, and aging—as well as multi-scale interactions across biological hierarchies, remains markedly constrained. Living cells are not frozen biological units; rather, they are constantly undergoing dynamic processes including division, differentiation, aging, and environmental response. A cell's state is intricately shaped by intracellular molecular networks, intercellular communications, tissue microenvironments, and individual background parameters. Consequently, integrating the temporal axis, biological age, and external interventions into a unified computational framework has emerged as a crucial trajectory for the evolution of virtual cell research.
